GE Healthcare Acquires Wave Biotech LLC

Broadening Capabilities in Growing Biopharmaceutical Manufacture Segment

18-Apr-2007

GE Healthcare, a unit of General Electric Company, announced it has acquired Wave Biotech LLC, a supplier of disposable manufacturing technologies for the biopharmaceutical industry. The acquisition of Wave Biotech LLC including its subsidiary Wave Europe Pvt. Ltd. shall allow GE Healthcare to expand its offering of products and services for the manufacture of biopharmaceuticals such as antibodies and vaccines. Financial terms were not disclosed.

Wave Biotech develops and manufactures bioreactors which are designed to replace traditional and more expensive stainless steel tanks and piping. According to the company, the patented products offer considerable advantages such as more rapid installation, potentially reducing time to market, and significantly lower costs by eliminating the need for cleaning and validating between batches.

Other news from the department business & finance

Most read news

More news from our other portals

Under the magnifying glass: The world of microscopy

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous